Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/6/2025

Management of Antithrombotic Therapy After CABG

Post-CABG Antithrombotic Management

  • The European Society of Cardiology recommends aspirin 75-100 mg daily as lifelong antiplatelet therapy after CABG, to be initiated as soon as there is no concern over bleeding 2, 3
  • Aspirin should be restarted as soon as possible after CABG, potentially within 24 hours if bleeding risk is acceptable, as suggested by the European Heart Journal 4
  • P2Y12 inhibitors, such as clopidogrel, should generally be stopped before CABG and not routinely restarted immediately post-CABG, according to the European Heart Journal and Circulation 4, 5

Timing of Anticoagulation

  • Low Molecular Weight Heparin, like tinzaparin, should be discontinued 12-24 hours before CABG and replaced with unfractionated heparin per institutional practice, as recommended by Circulation 6, 5

Bleeding Risk Considerations

  • Continuous telemetry is typically used in the immediate post-CABG period to monitor for arrhythmias, and the presence of CTT suggests the patient is still in the early post-operative period where bleeding risk is highest, according to the European Heart Journal 2, 7

Special Circumstances

  • Dual antiplatelet therapy with aspirin and clopidogrel may be considered in selected patients at greater risk of graft occlusion and low risk of bleeding, but not in the immediate post-operative period, as suggested by the European Heart Journal 3
  • A meta-analysis showed that ticagrelor-based DAPT provided superior vein graft patency compared to aspirin alone, but with increased bleeding rates, according to the European Heart Journal 4
  • For patients who develop atrial fibrillation after CABG, the impact of early oral anticoagulation initiation remains unclear, as reported by the European Heart Journal 7
  • Consider adding a proton pump inhibitor to reduce gastrointestinal bleeding risk if antithrombotic therapy is necessary, as recommended by the European Heart Journal 3